No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial.
about
Temporary treatment during primary HIV infection does not affect virologic response to subsequent long-term treatmentDNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent VirusThe detection and management of early HIV infection: a clinical and public health emergency.Development and validation of a risk score to assist screening for acute HIV-1 infection among men who have sex with menEarly time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial.Short-course antiretroviral therapy in primary HIV infection.Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cellsA novel Acute Retroviral Syndrome Severity Score predicts the key surrogate markers for HIV-1 disease progression.Challenges of diagnosing acute HIV-1 subtype C infection in African women: performance of a clinical algorithm and the need for point-of-care nucleic-acid based testingExploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy.Symptomatic illness and low CD4 cell count at HIV seroconversion as markers of severe primary HIV infection.Immunological and virological benefits resulted from short-course treatment during primary HIV infection: a meta-analysisAntiretroviral therapy: when to startA lower viral set point but little immunological impact after early treatment during primary HIV infectionDisease progression of HIV-1 infection in symptomatic and asymptomatic seroconverters in Osaka, Japan: a retrospective observational study.Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort studyHow can we better identify early HIV infections?A Randomized Trial of Time-Limited Antiretroviral Therapy in Acute/Early HIV Infection.Structured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes.Impact of Early Initiation of Antiretroviral Therapy in Patients with Acute HIV Infection in Vienna, Austria.Longitudinal dynamics of the HIV-specific B cell response during intermittent treatment of primary HIV infectionThe HIV treatment cascade in acutely infected people: informing global guidelines.The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment.Translational HIV-1 research: from routine diagnostics to new virology insights in Amsterdam, the Netherlands during 1983-2013Performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay in Detecting "Recent" HIV Infection and Calculating Population Incidence.Virological Blips and Predictors of Post Treatment Viral Control After Stopping ART Started in Primary HIV Infection.Update on antiretroviral treatment during primary HIV infection.No change in viral set point or CD4 cell decline among antiretroviral treatment-naïve, HIV-1-infected individuals enrolled in the Danish HIV Cohort Study in 1995-2010.Clinical and public health implications of acute and early HIV detection and treatment: a scoping review.Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durability.Primary HIV Infection: Clinical Presentation, Testing, and Treatment.Antiretroviral treatment for HIV infection: Swedish recommendations 2016.Immunosuppressive Tryptophan Catabolism and Gut Mucosal Dysfunction Following Early HIV Infection.Low bone mineral density, regardless of HIV status, in men who have sex with men.What do we measure when we measure cell-associated HIV RNA.A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection.Long-term therapeutic impact of the timing of ART in patients diagnosed with primary HIV-1 infection.Effect of antiretroviral therapy on bone turnover and bone mineral density in men with primary HIV-1 infection.A study on the dynamics of temporary HIV treatment to assess the controversial outcomes of clinical trials: An in-silico approach
P2860
Q28541870-13432F9C-F15D-407F-AFE3-59820D91D732Q28554534-0ABFAB15-E85C-4E94-84FC-C411BD073DA5Q33586581-C4774217-EDCE-4A19-9055-703370230268Q33801473-E973F518-E809-4FDD-9CF3-CB4842DCC761Q33926151-C4B52473-F2B7-4E75-AD1E-0EB9A15F7A53Q34037516-60A35DF7-ECEC-435E-98CD-D033F28BBFDFQ34059612-EE792FBE-25A4-4E24-BBB3-45410006BAEEQ34662516-59877C3A-725D-4271-B375-15C158CA840AQ34706934-EDA90DDE-95AA-40F0-97E5-E0F9F51B7F40Q34869927-B5A3883F-43ED-4570-8B0B-391A1F34242EQ35036284-424FB33E-6A7A-452F-B3A0-81032BB4662BQ35045387-872D3A73-B423-4001-8E5D-991C3466DC5FQ35064203-C15191FC-0410-408C-97F6-BF3231442689Q35204279-B395DF2D-12D9-468A-99ED-13F8BB57727DQ35323147-44C2498B-FFFD-4C7D-8CB3-5C1B9286FB20Q35633636-E0133027-86E3-4F7F-8899-520B40E1D440Q35794099-EF1A5D16-07A6-42E3-91F2-D98DAAF1638CQ35814304-C01330B1-9792-4CD0-88E0-D735E8FC48EBQ35850919-F5C2CED3-3E2A-4815-8A22-B94EBD3010F3Q35862206-F5AD2BA6-F79C-4880-A43D-E708CF6AC543Q35985891-C9F85A05-53A8-4630-B859-E33F8084A445Q36309003-2422E623-2715-4E3C-B87A-F55B5C920112Q36539990-4F56070A-A734-40F1-BA29-F4649FEAE7AEQ36692642-3FA907C6-1E43-44A4-B501-C874C2C7574DQ37153174-74DC6612-80AB-4FDA-A40B-91A14CFFB7E8Q37415771-365580FA-8CD5-41E5-A8B5-0BF6EB53C5DCQ37582477-7B1F026F-A201-4F27-BBB2-8F31180CD37BQ38209874-4BEE0F64-252D-4CD1-BBEF-5B631C4E6BC5Q38427594-C034560B-0454-4513-8F51-57C28F179AF7Q38686953-733CF392-140E-4030-A35C-A053CBDC1526Q39357415-4C862CB4-0BC2-4A36-AC5E-A965ABFA473FQ40051712-7D3AD541-2649-4B5B-84C2-A4E3A8D06AD6Q40470257-562E9EB3-361A-4744-B195-C7293DCA5FE8Q41524859-E5089E44-12FE-473C-A298-8BE407475239Q42286708-54AB9A71-52F6-4942-87D0-73B0E2C6D2CFQ47548192-8DFA8496-6360-41F8-BC69-1F4AF31B50B8Q47568717-0DB6E7F1-24FB-4612-AB2F-2B0FFF2E4CF5Q47568847-7CDFF7A8-97C9-4F91-80B8-F9B5180A4377Q52664377-30F740DF-7662-4E5A-895E-5DC9B7E31EBEQ57175535-2A9E28BC-6D35-49E7-B8EE-A8256FA6A6F9
P2860
No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
No treatment versus 24 or 60 w ...... he randomized Primo-SHM trial.
@ast
No treatment versus 24 or 60 w ...... he randomized Primo-SHM trial.
@en
No treatment versus 24 or 60 w ...... he randomized Primo-SHM trial.
@nl
type
label
No treatment versus 24 or 60 w ...... he randomized Primo-SHM trial.
@ast
No treatment versus 24 or 60 w ...... he randomized Primo-SHM trial.
@en
No treatment versus 24 or 60 w ...... he randomized Primo-SHM trial.
@nl
prefLabel
No treatment versus 24 or 60 w ...... he randomized Primo-SHM trial.
@ast
No treatment versus 24 or 60 w ...... he randomized Primo-SHM trial.
@en
No treatment versus 24 or 60 w ...... he randomized Primo-SHM trial.
@nl
P2093
P2860
P1433
P1476
No treatment versus 24 or 60 w ...... he randomized Primo-SHM trial.
@en
P2093
Ferdinand W N M Wit
Frank de Wolf
Hanneke Schuitemaker
Jan M Prins
Joep M A Lange
Kees Brinkman
Marchina E van der Ende
Marlous L Grijsen
Primo-SHM Study Group
Radjin Steingrover
P2860
P304
P356
10.1371/JOURNAL.PMED.1001196
P407
P577
2012-03-27T00:00:00Z